Skip to main content

Outbreak of colistin and carbapenem-resistant Klebsiella pneumoniae ST16 co-producing NDM-1 and OXA-48 isolates in an Iranian hospital



Colistin and carbapenem-resistant Klebsiella pneumoniae (Col-CRKP) represent a significant and constantly growing threat to global public health. We report here an outbreak of Col-CRKP infections during the fifth wave of COVID-19 pandemic.


The outbreak occurred in an intensive care unit with 22 beds at a teaching university hospital, Isfahan, Iran. We collected eight Col-CRKP strains from seven patients and characterized these strains for their antimicrobial susceptibility, determination of hypermucoviscous phenotype, capsular serotyping, molecular detection of virulence and resistance genes. Clonal relatedness of the isolates was performed using MLST.


The COVID-19 patients were aged 24–75 years with at least 50% pulmonary involvement and were admitted to the intensive care unit. They all had superinfection caused by Col-CRKP, and poor responses to antibiotic treatment and died. With the exception of one isolate that belonged to the ST11, all seven representative Col-CRKP strains belonged to the ST16. Of these eight isolates, one ST16 isolate carried the iucA and ybtS genes was identified as serotype K20 hypervirulent Col-CRKP. The blaSHV and blaNDM-1 genes were the most prevalent resistance genes, followed by blaOXA-48 and blaCTX-M-15 and blaTEM genes. Mobilized colistin-resistance genes were not detected in the isolates.


The continual emergence of ST16 Col-CRKP strains is a major threat to public health worldwide due to multidrug-resistant and highly transmissible characteristics. It seems that the potential dissemination of these clones highlights the importance of appropriate monitoring and strict infection control measures to prevent the spread of resistant bacteria in hospitals.

Peer Review reports


Klebsiella pneumoniae is a major Gram-negative bacterial pathogen that can cause invasive hospital-acquired infections among patients, especially those admitted to the intensive care unit (ICU) [1]. Carbapenem-resistant K. pneumoniae (CRKP) represents a major healthcare problem globally being associated with increased infectious morbidity and mortality due to limited treatment options [2]. Usually, resistance to carbapenems is mediated by carbapenemase production or by overexpression of AmpC cephalosporinases in combination with porin mutations. So far, the most common carbapenemases, in terms of carbapenem hydrolysis and geographical spread, are KPC, the MBLs NDM, VIM and IMP, and OXA-48 [3]. Carbapenem resistance has been described in many distinct K. pneumoniae genotypes determined with the help of multi-locus sequence typing (MLST). Carbapenemase-producing K. pneumoniae (CPKP) is often extensively drug-resistant (XDR) and poses serious problems in terms of clinical treatment and infection control. In recent years in Iran, OXA-48 and NDM-1 producing K. pneumoniae has been recognized, which belong to different clones (especially clones, ST11, ST893 and ST147) [4,5,6].

Colistin represents a few antimicrobials remaining active against infections caused by CPKP isolates. Colistin resistance in K. pneumoniae is mediated by several mechanisms. The most common strategies for resistance to colistin are modifications of the bacterial outer membrane through alteration of the lipopolysaccharid. The other mechanisms include overexpression of efflux-pump systems and point-mutations in pmrB, and MgrB genes. Another mechanism is overproduction of capsule polysaccharide. In addition, horizontal transfer of plasmid-mediated mobile colistin resistance gene, mcr, play a significant role in the dissemination of colistin resistance [78]. The use of colistin as an option to treat infections caused by carbapenem-resistant Gram-negative bacteria has led to increased resistance to this antibiotic in recent years, which is now challenging the effectiveness of this therapy [9]. Since there are no novel β-lactam agents (i.e., meropenem-vaborbactam, imipenem-cilastatin-relebactam and cefiderocol) and tigecycline in the list of Iranian pharmacopoeias, colistin is almost the last resort of CPKP treatment in Iran. This may be due to the lack of extensive epidemiological studies on the prevalence of carbapenemase genes in our country. Although tigecycline and ceftazidime-avibactam can be obtained freely in the market recently, it cannot be obtained for many patients due to high costs and lack of insurance coverage. Therefore, increasing resistance to colistin in CPKP strains causes great concerns about the choice of effective antibiotics to treat nosocomial infections.

In this study, we investigate a fatal outbreak among patient’s hospitalization in ICU in an Iranian hospital during the fifth wave of COVID-19 pandemic with the aim of the molecular tracking for the emerging ST16 CPKP strains responsible for this outbreak.

Materials and methods

Outbreak investigation

A retrospective, single-center study including all adult patients with diagnosis of COVID-19 requiring ICU admission and hospitalized at an Iranian hospital in Isfahan was performed. During the fifth wave of COVID-19 pandemic from 14th June to 16th December 2021, our hospital was exclusively allocated to the cure and handling of COVID-19 patients. In late June and early August, we identified several cases of infection due to spread of colistin and carbapenem-resistant K. pneumoniae (Col-CRKP) in the ICU. The ICU consists of three wards with 22 beds (a main hall with 18 beds and 4 separate isolated rooms). In addition, there are only two hand washing sinks in the whole hall as well as one hand washing sink in two of the isolated rooms. Before the outbreak described, sporadic cases of infection (one or two cases per year) caused by Col-CRKP isolates were reported among patients. Therefore, it was detected an outbreak that had involved in seven patients. Five patients stayed in the second ward, and one patient hospitalized in each of the first and third wards of the ICU. All patients had an overlapping time in the ICU during this outbreak. All clinical data were extracted from electronic medical records available in the hospital intranet. This project was done based on hospital ethical guidelines as previously approved by Ethical Committee of the Isfahan University of Medical Sciences (approval number IR.ARI.MUI.REC.1402.014).

Bacterial isolates and antimicrobial susceptibility

Bacterial strains were isolated from the various sample specimens at the clinical microbiology laboratory of the hospital. All isolates were subjected to antibiotic susceptibility testing by Kirby-Bauer disc diffusion method on Mueller Hinton Agar plates (HiMedia, India) against the ceftazidime, cefotaxime, cefepime, amikacin, gentamicin, ciprofloxacin, levofloxcine, piperacillin-tazobactam, ampicillin-sulbactam, imipenem and meropenem as well as nitrofurantoin for urine samples. Minimum inhibitory concentrations (MICs) were determined by E-test (meropenem and imipenem) and broth microdilution (colistin). E. coli ATCC 25922 and Pseudomonas aeruginosa ATCC 27853 were used as quality control strains. We interpreted these in accordance with the guideline document M100-S30 established by Clinical and Laboratory Standards Institute (CLSI-2017) [10]. Initial screening for detection of carbapenemases was done by the modified carbapenem inactivation method (mCIM) [10].

Determination of hypermucoviscous phenotype

The hypermucoviscosity phenotype of the isolates was assessed by string test as described previously [11]. Hypermucoviscosity was defined by the formation of viscous strings >5 mm in length when a loop was used to stretch the colony on agar plate [12].

Capsular serotyping and molecular detection of virulence and resistance genes

Plasmid DNA extraction Mini Kit (FAVORGEN Biotech Corporation, Taiwan) has been used for the detection of genes carried on plasmids. In addition, the boiling method was used for isolation of genomic DNA. Detection of capsular serotype-specific genes including K1, K2, K5, K20, K54, K57 and virulence genes (iucA, peg-344, iutA, iroB, magA, kfuB, ybtS, rmpA and alls) was carried out by PCR assays [213]. The presence of genes encoding beta-lactamases, including ESBLs (blaCTX-M-15, blaTEM, blaSHV) and carbapenemases (blaKPC-1, blaVIM, blaIMP, blaNDM-1 and blaOXA-48) genes were investigated by PCR as previously described [14]. Also, detection of genes conferring resistance to colistin was also performed for plasmid genes mcr-1, mcr-2, mcr-3, and mcr-4 [15].

Multi-locus sequence typing (MLST)

MLST for all seven isolates was done with seven housekeeping genes (gapA, infB, mdh, phoE, pgi, rpoB, and tonB) according to the protocol on the MLST website (


During the fifth wave of COVID-19 pandemic, the patients were aged 24–75 years with at least 50% pulmonary involvement were admitted to the ICU from 14th June to 16th December 2021. Out of patients, two patients were male and five were female. Of all patients, six cases had underlying diseases such as blood pressure, diabetes, chronic kidney disease, chronic heart disease or pregnancy (Table 1). Timeline of the patient’s hospitalization in ICU are shown in Fig. 1. Following admission to the ICU, they all received antibiotic prophylaxis (Fig. 2), four of the patients also received ACTEMRA® (tocilizumab). The seven patients developed superinfection and all showed various clinical symptoms such as pulmonary edema, purulent discharge, leukocytosis and fever, with at least two symptoms in each patient. The clinical and laboratory profile for the seven Col-CRKP- infected patients are summarized in Table 1. The eight Col-CRKP species isolated from tracheal (n = 2), urine (n = 3), endocervical (n = 2) and stool (n = 1) samples of the patients, since all the patients had overlapping stays in the ICU, suggesting that Col-CRKP might be the causative agent of the outbreak. In this study, urinary tract infection, ventilator-associated pneumonia (VAP) and cervicitis infection were reported from three, two and two patients, respectively. Also, colonization with Col-CRKP occurred in patient-7. The mean time from ICU admission to superinfection diagnosis was 13.7 days. All seven patients died of severe infection after Col-CRKP could be recovered from their microbiological samples (Table 1).

Table 1 Baseline characteristics, laboratory data, and outcomes of seven COVID-19 patients with Col-CRKP admitted in ICU
Fig. 1
figure 1

Timeline of the patient’s hospitalization in ICU

Fig. 2
figure 2

Epidemiology of the carbapenem-resistant K. pneumoniae outbreak cases. COT: Co-trimoxazole; MEM: Meropenem; LEV: Levofloxacin; PTZ: Piperacillin/tazobactam; LIN: Linezolid; VAN: Vancomycin; AM: Ampicillin; CPM: Cefepime; TIG: Tigecycline; COL: Colistin; CLI: Clindamycin

Resistance phenotypes and detection of antimicrobial resistance genes

Results of the antimicrobial susceptibility testing revealed a high-level resistance of K. pneumoniae isolates to all tested antibiotics, on the other hand, all clinical isolates were tigecycline susceptible K. pneumoniae in line with the EUCAST (Table 2). The MICs of meropenem, imipenem and colistin in seven Col-CRKP isolates were listed in Table 2. The mCIM results showed that all isolates were positive for carbapenemase phenotype.

Table 2 Microbiological and genomic characteristics of the Col-CRKP strains

Among eight Col-CRKP isolates only one isolate was positive for the string test and identified as hypervirulent K. pneumoniae (Table 2). MLST analysis revealed that the eight Col-CRKP isolates belonged to two STs. Seven isolates were identified as ST16 that five isolates co-carried blaOXA-48 and blaNDM-1 and two isolate carried only blaNDM-1 gene. Also, one isolate that recovered from patient-2 belonged to ST11, which only carried the blaOXA-48 gene. All Col-CRKP strains carried at least one ESBL genes except one isolate that belonged to ST11. The blaSHV gene was the most prevalent ESBL gene (7/8), followed by blaCTX-M-15 and blaTEM (5/8) (Table 2). All isolates were negative for the mcr-1, mcr-2, mcr-3, and mcr-4 genes.

Capsular genotyping and detection of virulence genes

Capsular genotyping (K genotyping) of isolates showed that capsular serotype K20 was detected in only two isolates. PCR for virulence-associated genes revealed that iucA and ybtS were identified in only two and one isolate, respectively. The other virulence factor genes were not detected in any of the strains.


Our results show the emergence of ST16 Col-CRKP strains that caused fatal hospital infections. In the present study, all seven patients were infected between late June and early August. Outbreak of Col-CRKP, it probably indicates a near-patient environmental source, pointing to poor hand hygiene and lack of compliance with device-related bundle care protocols as contributing factors. It is possible that Col-CRKP isolate was transferred to patients four and six through the gynecologist during vaginal ultrasound or through the nurse’s assistant during vaginal care or stool cleaning. Similar to previous reports [1617], since the implementation of infection prevention and control (IPC) procedures in this ICU, no fatal infections due to ST16 CRKP have occurred until the end of the fifth wave of COVID-19 pandemic. However, more evidence is needed to confirm that this IPC policy is effective in preventing CRKP infections in our ICU.

High mortality rate (approximately 69%) in bloodstream infections due to Col-CRKP was also reported in a study in India [18].

According to our results, six of seven COVID-19 patients had normal WBC counts at ICU admission, while six patients had leukocytosis and one patient had leukopenia at microbial sampling time. In addition, none of the patients had fever at the time of hospitalization in the ICU, but five of the patients had fever at microbial sampling time, which could be resulted from bacterial co-infection in patients. These results are consistent with He′s study in China [19]. In the present study, the median days from ICU admission to bacterial growth was 13.7 days [8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26]. It is well known that most hospitalized severe COVID-19 patients are prescribed steroids, undergo invasive procedures and sometimes have a prolonged ICU stay, rendering them vulnerable to be at higher risk of secondary infections [20]. Five patients received tocilizumab and seven patients received at least one steroid, also, invasive tools were used for all patients.

Similar to other studies [21], we found that patients were often treated with early empiric antibacterial. Piperacillin-tazobactam and meropenem were the most commonly prescribed antibiotics. Antimicrobial susceptibility testing in our study confirmed resistance to all antibiotics in all eight isolates. Since none of the available antibiotics was effective in treating infections caused by ST16 Col-CRKP strains, we have implemented a new IPC policy to control the outbreak in the hospital. And it also shows the urgent need for novel β-lactam agents (i.e., ceftazidime-avibactam and cefiderocol) to treat patients with this infection. Notably, all Col-CRKP strains carried at least one carbapenemase gene (blaNDM-1 or blaOXA-48). We also found that five out of eight isolates co-carried blaNDM-1 and blaOXA-48, a finding consistent with that reported previously in Iran [142223]. This highlights that isolates with blaNDM-1 and blaOXA-48 genes continue to be a problem in Iran. Col-CRKP with pandrug-resistant and XDR phenotype co-producing blaNDM-1 and blaOXA-48 carbapenamases have been reported to cause severe nosocomial infections in several countries [182425]. The previously reported cases of blaNDM-1 and blaOXA-48–harboring K. pneumoniae in Iran were mainly serotypes ST11, ST147 and ST893 [42226], while ST16 was the dominant epidemic serotypes in our study. Since ST11 is the major clone of CRKP in Iran, the prevalence of ST16 is very significant, especially as it was related to hospital-acquired infections.

Thus, ST16 may be a high-risk, CPKP clone actively disseminating across our hospital, with related outbreaks being reported in Thailand [27].

Outbreaks of K. pneumoniae ST16 carrying carbapenemase and ESBL genes, have recently been sporadically reported. In the last years, numerous hospital surveillance programs from different countries reported ST16 and ST11 carrying different antimicrobial resistance profiles. K. pneumoniae ST16 associated with NDM-1, CTX-M-15, and OXA-232 caused infections in a hospital in Italy [28], and in Thailand a carbapenem-resistant ST16 clone co-producing NDM-1 and OXA-232 was also reported. Hypervirulence genes (iucA, ybtS) were identified in only one ST16 isolate in our study, contrary to our findings, Abe et al. in Thailand reported that all the ST16 isolates are non-hypervirulent [29]. In our previous study, a case of infection caused by K. pneumoniae ST16 was reported, unlike this study, the patient was treated with tigecycline [30].


In conclusion, we reported the fatal outbreak of an XDR K. pneumoniae ST16 in a hospital in Iran, which carried the carbapenemase genes in combination with ESBLs. To the best of our knowledge, this study is the first to report on the NDM-1 and OXA-48-producing hypervirulent K. pneumoniae ST16-K20 causing fatal VAP. Therefore, it is enormously important to strengthen antibiotic control to prevent the development of antimicrobial resistance and to emphasize infection control measures are needed to prevent Col-CRKP from further disseminating in hospital settings and the community.

Availability of data and materials

The datasets used and analyzed during the current study are available from the corresponding author upon reasonable request.



Colistin and carbapenem-resistant Klebsiella pneumoniae


Multi-locus sequence typing


Mobilized colistin-resistance


Intensive care unit


Carbapenem-resistant K. pneumoniae


Carbapenemase-producing K. pneumoniae


Extensively drug-resistant


Minimum inhibitory concentrations


Clinical and Laboratory Sltandards Institute


Modified carbapenem inactivation method


Ventilator-associated pneumonia


Infection prevention and control.


  1. Bengoechea JA, Pessoa JS. Klebsiella pneumoniae infection biology: living to counteract host defences. FEMS Microbiol Rev. 2019;43:123–44.

    Article  CAS  PubMed  Google Scholar 

  2. Candan E, Aksöz N. Klebsiella pneumoniae: characteristics of carbapenem resistance and virulence factors. Acta Biochim Pol. 2015;867-874

  3. Nishida S, Y., O. Genomic analysis of a pan-resistant Klebsiella pneumoniae sequence type 11 identified in Japan in 2016. Int J Antimicrob Agents. 2020;55:105854.

    Article  CAS  PubMed  Google Scholar 

  4. Bolourchi N, Shahcheraghi F, Giske C, et al. Comparative genome analysis of colistin-resistant OXA-48-producing Klebsiella pneumoniae clinical strains isolated from two Iranian hospitals. Ann Clin Microbiol Antimicrob. 2021;74:1–11.

    Google Scholar 

  5. Bahramian A, Shariati A, Yasbolaghi Sharahi J, et al. First report of New Delhi metallo-β-lactamase-6 (NDM-6) among Klebsiella pneumoniae ST147 strains isolated from dialysis patients in Iran. Infect Genet Evol. 2019;69:142–5.

    Article  CAS  PubMed  Google Scholar 

  6. Solgi H, Nematzadeh S, Giske C, et al. Molecular epidemiology of OXA-48 and NDM-1 producing Enterobacterales species at a University Hospital in Tehran, Iran, between 2015 and 2016. Front Microb. 2020;11:1–13.

    Article  Google Scholar 

  7. Binsker U, Käsbohrer A, Hammerl JA. Global colistin use: a review of the emergence of resistant Enterobacterales and the impact on their genetic basis. FEMS Microbiol Rev. 2022;46:1–37.

    Article  Google Scholar 

  8. Ah Y-M, Kim A-J, Lee J-Y. Colistin resistance in Klebsiella pneumoniae. Int J Antimicrob Agents. 2014;44:8–15.

    Article  CAS  PubMed  Google Scholar 

  9. Rojas LJ, Salim M, Cober E, et al. Colistin resistance in Carbapenem-resistant Klebsiella pneumoniae: laboratory detection and impact on mortality. Clin Infect Dis. 2017;46:711–8.

    Google Scholar 

  10. Clinical and Laboratory Standards Institute [CLSI] (2017). Performance standards for antimicrobial susceptibility testing, 27th Edn, Wayne, PA: Clinical and Laboratory Standards Institute.

  11. Wu H, Li D, Zhou H, et al. Bacteremia and other body site infection caused by hypervirulent and classic Klebsiella pneumoniae. Microb Pathog. 2017;104:254–62.

    Article  PubMed  Google Scholar 

  12. Fang CT, Chuang YP, Shun CT, et al. A novel virulence gene in Klebsiella pneumoniae strains causing primary liver abscess and septic metastatic complications. J Exp Med. 2004;199:697–705.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Turton JF, Perry C, Elgohari S, et al. PCR characterization and typing of Klebsiella pneumoniae using capsular type-specific, variable number tandem repeat and virulence gene targets. J Med Microbiol. 2010;59:541–7.

    Article  CAS  PubMed  Google Scholar 

  14. Sanikhani R, Moeinirad M, Solgi H, et al. The face of hypervirulent Klebsiella pneumoniae isolated from clinical samples of two Iranian teaching hospitals. Ann Clin Microbiol Antimicrob. 2021;20:58.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Pishnian Z, Haeili M, Feizi A, et al. Prevalence and molecular determinants of colistin resistance among commensal Enterobacteriaceae isolated from poultry in northwest of Iran. Gut Pathog. 2019;11:1–8.

    Article  Google Scholar 

  16. Gu D, Dong N, Zheng Z, et al. A fatal outbreak of ST11 carbapenem-resistant hypervirulent Klebsiella pneumoniae in a Chinese hospital: a molecular epidemiological study. Lancet Infect Dis. 2018;18:37–46.

    Article  PubMed  Google Scholar 

  17. Patel A, Emerick M, Cabunoc M, et al. Rapid spread and control of multidrug-resistant gram-negative Bacteria in COVID-19 patient care units. Emerg Infect Dis. 2021;27:1234–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Azam M, Gaind R, Yadav G, et al. Colistin resistance among multiple sequence types of Klebsiella pneumoniae is associated with diverse resistance mechanisms: A report from India. Front Microbiol. 2021;12:1–3.

    Article  Google Scholar 

  19. He S, Liu W, Jiang M, et al. Clinical characteristics of COVID-19 patients with clinically diagnosed bacterial co-infection: A multi-center study. PLoS One. 2021;16:e0249668.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Moore JL, Stroever SL, Rondain PE, et al. Incidence of secondary bacterial infections following utilization of tocilizumab for the treatment of COVID-19 – A matched retrospective cohort study. J Global Infect Dis. 2021;13:67–71.

    Article  CAS  Google Scholar 

  21. Vaughn VM, Gandhi T, Petty L, et al. Empiric antibacterial therapy and community-onset bacterial coinfection in patients hospitalized with coronavirus disease 2019 (COVID-19): A multi-hospital cohort study. Clini Infect Disea. 2021;72:e533–41.

    Article  CAS  Google Scholar 

  22. Solgi H, Shahcheraghi F, Bolourchi, e al. Molecular characterization of carbapenem-resistant serotype K1 hypervirulent Klebsiella pneumoniae ST11 harbouring blaNDM-1 and blaOXA-48 carbapenemases in Iran. Microb Pathog. 2020;149:104507.

    Article  CAS  PubMed  Google Scholar 

  23. Solgi H, Badmasti F, Aminzadeh Z, et al. Gastrointestinal colonization with three different NDM-1-producing enterobacterial species isolated from an inpatient in Tehran Iran. J Glob Antimicrob Resist. 2018;12:53–4.

    Article  PubMed  Google Scholar 

  24. Guducuoglu H, Gursoy NC, Yakupogullari Y, et al. Hospital outbreak of a colistin-resistant, NDM-1-and OXA-48-producing Klebsiella pneumoniae: high mortality from pandrug resistance. Microb Drug Resist. 2018;24:966–72.

    Article  CAS  PubMed  Google Scholar 

  25. Moubareck CA, Mouftah SF, Pál T, et al. Clonal emergence of Klebsiella pneumoniae ST14 co-producing OXA-48-type and NDM carbapenemases with high rate of colistin resistance in Dubai, United Arab Emirates. Int J Antimicrob Agents. 2018;52:90–5.

    Article  CAS  PubMed  Google Scholar 

  26. Talebzadeh H, Melali SH. Association of fluoroquinolone resistance and ESBL production in hypervirulent Klebsiella pneumoniae ST11 and ST893 in Iran. Acta Microbiol Immunol Hung. 2022:135–43.

  27. Boonyasiri A, Jauneikaite E, Brinkac LM, et al. Genomic and clinical characterisation of multidrug-resistant carbapenemase-producing ST231 and ST16 Klebsiella pneumoniae isolates colonising patients at Siriraj hospital, Bangkok, Thailand from 2015 to 2017. BMC Infect Dis. 2021;21:1–11.

    Article  Google Scholar 

  28. Espinal P, Nucleo E, Caltagirone M, et al. Genomics of Klebsiella pneumoniae ST16 producing NDM-1, CTX-M-15, and OXA-232. Clinic Microbiol Infect. 2019;25(385):e381e385.

    Google Scholar 

  29. Abe R, Akeda U, Takeuchi D, et al. Clonal dissemination of carbapenem-resistant Klebsiella pneumoniae ST16 co-producing NDM-1 and OXA-232 in Thailand. JAC Antimicrob Resist. 2022;16:dlac084.

    Article  Google Scholar 

  30. Pourajam S, Zafarbakhsh A, Hosseinzadeh M, et al. Secondary bacterial infection caused by ST16 NDM-1 and OXA-48-producing colistin and carbapenem-resistant Klebsiella pneumoniae treated with tigecycline in a pregnant woman with COVID-19. J Pharm Policy Pract. 2023;16:1–4.

    Article  Google Scholar 

Download references


Not applicable.


This study was funded by the Isfahan University of Medical Sciences (No. 58478).

Author information

Authors and Affiliations



H.S and F.B conceptualized the study; H.S, R.S, M.A and F.B. performed the experiments; H.S analyzed the data; H.S, M.H and M.S drafted the manuscript. All authors have revised and approved the final manuscript.

Corresponding authors

Correspondence to Farzad Badmasti or Hamid Solgi.

Ethics declarations

Ethics approval and consent to participate

The study was approved by the Ethical Committee of the Isfahan University of Medical Sciences (approval number IR.ARI.MUI.REC.1402.014). We can confirm that all methods in this study were performed in accordance with the relevant guidelines and regulations. A waiving of the patient informed consent was approved from the Isfahan University Research ethics committee since the collected isolates were obtained from the discharged clinical specimens of unidentified patients and there was no any type of contact with patients.

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sanikhani, R., Akbari, M., Hosseinzadeh, M. et al. Outbreak of colistin and carbapenem-resistant Klebsiella pneumoniae ST16 co-producing NDM-1 and OXA-48 isolates in an Iranian hospital. BMC Microbiol 24, 59 (2024).

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: